Cetera Investment Advisers’s BridgeBio Pharma BBIO Stock Holding History

Cetera Investment Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.9M	Sell	52,391 -9,342	-15%	-$654K	﹤0.01%	1797
2026 Q1	$4.58M	Sell	61,733 -11,004	-15%	-$798K	﹤0.01%	1566
2025 Q4	$5.56M	Sell	72,737 -1,984	-3%	-$130K	0.01%	1392
2025 Q3	$3.88M	Sell	74,721 -8,089	-10%	-$395K	﹤0.01%	1627
2025 Q2	$3.58M	Buy	82,810 +31,251	+61%	+$1.14M	0.01%	1421
2025 Q1	$1.78M	Buy	51,559 +14,396	+39%	+$485K	﹤0.01%	1830
2024 Q4	$1.02M	Buy	+37,163	New	+$960K	﹤0.01%	2142

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cetera Investment Advisers's BBIO Position: Q2 2026 in Review

Cetera Investment Advisers reduced its BridgeBio Pharma (BBIO) stake by 15% in Q2 2026, selling an estimated $654K and leaving 52,391 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Cetera Investment Advisers first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.56M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Cetera Investment Advisers held 52,391 shares of BridgeBio Pharma worth $3.9M as of Q2 2026.
Cetera Investment Advisers sold 9,342 BridgeBio Pharma shares in Q2 2026, an estimated $654K.
BridgeBio Pharma made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #1797 holding.
Cetera Investment Advisers first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
Cetera Investment Advisers's BridgeBio Pharma position peaked at $5.56M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.